Sandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine
The Pharma Data
MAY 8, 2021
The Sandoz division has a leading global portfolio with eight marketed biosimilars and a further 15-plus in various stages of development. Eylea ® is a trademark of Bayer AG and in the US of Regeneron Pharmaceuticals, Inc. Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars.
Let's personalize your content